The Financial Time reports that Takeda Pharmaceutical (OTCPK:TKPHF) lost its patience with Valeant Pharmaceuticals (VRX -7.9%) over its alleged inability to provide key information about Salix. A person close to the matter said the negotiations suffered because Valeant was unable to provide enough information about Salix's business and financials due to all the distractions and disruptions Valeant has endured over the past year.
Another source said the potential deal still has legs if Valeant can get its act together and deliver the information.
Takeda declined to comment on the situation while Valeant could not be immediately reached for comment.
Now read: Is This Valeant's Next Pariah? »